Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 4.75 | 10.73% | 49.00 | 10:27:45 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 44.25 | 44.25 | 50.00 | 44.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 09/11/2024 08:57 by pwhite73 Rajraj b "Why have they bothered to collaborate with Tempus then?"There is no collaboration with Tempus. Its just a joint statement by both parties paid for by Avacta to sucker in retail investors. What happened to the collaboration with William Tap of Memorial Sloan Kettering Cancer Center first announced in RNS 06/04/2023. In fact way before April last year they announced a collaboration with Memorial Sloan Kettering Cancer Center back in November 2016. RNS 02/11/2016 - "The collaboration will be led by Renier J. Brentjens, MD, PhD, Director of Cellular Oncology at Memorial Sloan Kettering Cancer Center in New York." All the collaborations are just announcements to give the impression of a functioning UK biotech company which they are not. |
Posted at 05/11/2024 07:22 by 1347 Of course Phase 2 is going ahead, Avacta have informed the market several times it will commence in 2024 and there's only a few weeks left now. Meanwhile in the real world they are hoping Avacta investors have collective amnesia and forget about it, and every single thing else they've ever tried to get to market in the last 5 years. I've told you, it's back to the drawing board with two brand new pre-clinical candidates that they can use to keep them in the lifestyles to which they've become accustomed for years to come. |
Posted at 17/10/2024 07:52 by 1347 So again what happened to AVA3996, or are they now tacitly admitting that AVA6000 was such a failure (as their Affimer based tests were) that they are not proceeding with the two candidates they got from Arisaph?"18 January 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023." What happened with their last pre-clinical pipeline candidates, AVA-021, AVA-028, AVA-032? Seems they were all quietly dropped, hoping no-one would notice? Well some of us have. Looks to me as if they just want to find some new pre-clinical candidates so they can kick off another 3 year Phase trial, have more placings to ‘advance’ I notice the announcements come just before the next payday loan payment is due, which I doubt will be paid by cash this time. I reckon ‘investorsR |
Posted at 09/10/2024 07:58 by baldrick1 Still many investors are putting their money here for the good of humanity. |
Posted at 03/10/2024 17:34 by mirabeau Avacta Group – Exploring NASDAQ Dual-Listing And Divesting Its Diagnostics Division, Analyst Has 188p Valuation, Shares Now 45.5pMark Watson-Mitchell 03/10/2024 On Wednesday 30th October, Avacta Group (LON:AVCT), the cancer treatments and diagnostics life sciences business, will be presenting a live Research & Development Spotlight entitled Next Generation of pre|CISION Medicines. It is expected that there will be keen investor interest to hear what the group has to say about its pre|CISION platform. The Business Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. It has two main segments: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals. Avacta Therapeutics: which is the clinical stage oncology biotech division that is harnessing the proprietary pre|CISION platform technology to develop novel, highly targeted cancer drugs. The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. Avacta Diagnostics: which focuses on supporting healthcare professionals and broadening access to diagnostics, has two business units – Launch Diagnostics and Coris Bioconcept. Launch Diagnostics is a well-established sales channels in the professional, centralised hospital laboratory testing market in the UK and France. Coris, based in Gembloux, Belgium, develops, manufactures and markets rapid diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals. In the highly competitive diagnostics market, Avacta’s proprietary Affimer® platf This Week’s Interim Results Last Monday morning the group reported its Interim Results for the six months to end-June, showing much in line with expectations, with revenues off slightly at £11.3m (£11.9m) and running at a first-half loss of £12.5m (£11.5m). The Diagnostics division revenues advanced to £11.2m (£9.9m), however, it must be noted that the company has started the process to divest this side of the business, in order to maximise value for shareholders, while ensuring its focus as a therapeutics-focused company and support its appeal to specialist international investors. After the £31.1m cash raise in March this year, the group ended the period with £32.5m cash and cash equivalents, against £26.6m at the same time last year. The first six months of the year saw a number of managerial and operational changes, while its financial position remains in line with the Board’s expectations. Management Comments New Chairman Shaun Chilton stated that: “Over the four months since Chris Alongside the Board and wider team, we have carried&# We are very encouraged by the potential of the innovative medicines in the Avacta pipeline which we plan to present at our live R&D Spotlight in October focusing on the Next Generation of the pre|CISION We have commenced a process to divest the Diagnostics Division and have started to receive indicative offers. Our longer-term financing strategy is being formulated and includes a potential dual listing of the Company on NASDAQ, which the Board sees as a key strategic option for the Company.” Avacta aims to leverage its proprietary pre|CISION™ platform to develop innovative oncology therapies that make a significant difference to cancer patients’ treatment experience and outcomes. The pre|CISION™ platform has the potential to enable patients to achieve improved outcomes with fewer side effects by leveraging the tumor specific enzyme Fibroblast Activation Protein (FAP) to protect normal tissues from toxic drugs. The group is poised to move into the next stage of development, implementing these findings of this drug release mechanism across our innovative pipeline. New CEO Christina Coughlin, MD, PhD, stated that: “We are seeing notably positive progress on our drug development candidate AVA6000 with the completion of the Phase 1a trial with no maximum tolerated dose and opening of the RDE expansion. This novel peptide drug conjugate cont The AVA6000 data in the clinic has led to a growing confidence in the pre|CISION™pla Our next generation programs will leverage the pre|CISION™ platform as a foundation for other tumor-specific warhead delivery systems. This platform will underpin our wider clinical strategy and our ambition of bringing these novel cancer medicines closer to patients and delivering value for shareholders.” Analyst Views At Trinity Delta, its analysts Lala Gregorek and Philippa Gardner consider that Avacta is transitioning into a developer of innovative highly targeted specialist oncology products. They state that once the Diagnostics division has been divested, Avacta will become a fully focused biotech company. That is an important element of the strategy to broaden Avacta’s appeal to specialist healthcare investors via a potential additional listing on NASDAQ, securing sustainable funding for further pipeline development. Trinity Delta concludes by noting that “pending the October R&D event in London we maintain our Avacta valuation of £675m, equivalent to 188p/share.” In My View There is a lot going on within this £161m capitalised group. The recent corporate shake-up appears to have been initially beneficial, and if the divestment goes ahead, and a NASDAQ quote is achieved, this group could well be significantly improving its 45.5p share price within months. Latest News Subscribe to the UK Investor Magazine email newsletter |
Posted at 01/10/2024 09:00 by the cronk When a company's struggling they often bring our the "listing on NASDAQ" quote to excite their investors.Most don't happen of course, but it keeps believers happy for longer, giving an opoortunity for some to exit.... |
Posted at 30/9/2024 06:28 by robers98 "We are seeing notably positive progress on our drug development candidate AVA6000 with the completion of the Phase 1a trial with no maximum tolerated dose and opening of the RDE expansion. This novel peptide drug conjugate continues to demonstrate a highly favorable tolerability profile and robust preliminary signs of efficacy, with several durable responses, as it moves through clinical development."The AVA6000 data in the clinic has led to a growing confidence in the pre|CISION™pla "This platform will underpin our wider clinical strategy and our ambition of bringing these novel cancer medicines closer to patients and delivering value for shareholders. Along with the rest of the team, I'm excited about the opportunity and look forward to expanding the opportunity that pre|CISION offers." Avacta will be hosting a live R&D Spotlight: Next Generation of pre|CISION™ Medicines in London on 30 October 2024. This event is open to both analysts and investors, further details are provided on the Company website at hxxps://avacta.com/2 |
Posted at 29/9/2024 08:15 by pareden Notice of ResultsInvestor Presentation via Investor Meet Company Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, will announce its unaudited interim results on 30 September 2024 for the six months ended 30 June 2024. |
Posted at 12/9/2024 17:42 by waldron Investor Presentation via Investor Meet CompanyAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, will announce its unaudited interim results on 30 September 2024 for the six months ended 30 June 2024. Christina Coughlin, MD, PhD, Avacta's CEO, will discuss the results and the Company's operational and clinical progress via the Investor Meet Company platform on 30 September 2024 at 11:00 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 29 September 2024, 09:00 BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via: Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited. The Company will also post its results presentation on its website at the following page: |
Posted at 29/5/2024 15:10 by bones698 White utter nonsense as usual over 90% of small caps stocks will lose investors money that's why it's a complete gamble and with bad odds. Everyone thinks they have got one of the 10% that comes good but the relaity is they haven't and will lose money.More importantly is when you buy and sell any of them and getting that timing right is crucial to being able to make money in small cap companies. Loom at any number that have raised money recently at huge discounts on already depressed share prices. Most investors are down over 90% on them as you well know. That said if your buying them now you stand a good chance to make money provided they can show some good news in the coming months. The ones that tend to lose are those investing for the long term at the wrong time in the cycle, paying to high a price for hopes and dreams that are years away and need cash to get there. Avacta is such a case imo and we have already seen the share price fall massively because of this Imo there is more of the same to come and with its 120m mkt cap it looks almost certain to fall further as more cash will be required and they are so far away from any revenues or break even from the drugs in trials. I don't hold a lot of shares I post on but I am entitled to my opinion and it's usually in stark contrast to many ramping those shares. The fact I don't hold doesn't stop me having an opinion and commenting on them as those that hold them usually are biased and fail to see the downside. Again just look back here and at mnay other companies. With that in mind and the success rate being so low it's usually the negative posters which are correct and should be listened to a lot more, sadly though how many actually do or end up losing money because they don't shows how silly some investors are when the facts back this up |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
